327 related articles for article (PubMed ID: 33191112)
1. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
Kohno S; Bando H; Yoneyama F; Kikukawa H; Kawahara K; Shirakawa M; Aoyama N; Brown M; Paschke A; Takase A
J Infect Chemother; 2021 Feb; 27(2):262-270. PubMed ID: 33191112
[TBL] [Abstract][Full Text] [Related]
2. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
[TBL] [Abstract][Full Text] [Related]
3. Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2020 Apr; 56(4):241-255. PubMed ID: 32309820
[TBL] [Abstract][Full Text] [Related]
4. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.
Vazquez JA; González Patzán LD; Stricklin D; Duttaroy DD; Kreidly Z; Lipka J; Sable C
Curr Med Res Opin; 2012 Dec; 28(12):1921-31. PubMed ID: 23145859
[TBL] [Abstract][Full Text] [Related]
6. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Motsch J; Murta de Oliveira C; Stus V; Köksal I; Lyulko O; Boucher HW; Kaye KS; File TM; Brown ML; Khan I; Du J; Joeng HK; Tipping RW; Aggrey A; Young K; Kartsonis NA; Butterton JR; Paschke A
Clin Infect Dis; 2020 Apr; 70(9):1799-1808. PubMed ID: 31400759
[TBL] [Abstract][Full Text] [Related]
7. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A
Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I; Wunderink RG; Roquilly A; Rodríguez Gonzalez D; David-Wang A; Boucher HW; Kaye KS; Losada MC; Du J; Tipping R; Rizk ML; Patel M; Brown ML; Young K; Kartsonis NA; Butterton JR; Paschke A; Chen LF
Clin Infect Dis; 2021 Dec; 73(11):e4539-e4548. PubMed ID: 32785589
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial.
Chen Z; Wu J; Zhang Y; Wei J; Leng X; Bi J; Li R; Yan L; Quan Z; Chen X; Yu Y; Wu Z; Liu D; Ma X; Maroko R; Cooper A
BMC Infect Dis; 2010 Jul; 10():217. PubMed ID: 20663130
[TBL] [Abstract][Full Text] [Related]
10. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
11. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
Heo YA
Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278
[TBL] [Abstract][Full Text] [Related]
12. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Smith JR; Rybak JM; Claeys KC
Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
Bradley JS; Makieieva N; Tøndel C; Roilides E; Kelly MS; Patel M; Vaddady P; Maniar A; Zhang Y; Paschke A; Chen LF
J Clin Pharmacol; 2023 Dec; 63(12):1387-1397. PubMed ID: 37562063
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
15. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Popejoy MW; Long J; Huntington JA
BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
[TBL] [Abstract][Full Text] [Related]
16. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
17. A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants.
Wang X; Liu N; Wei Y; Zhang S; Li H; Yan B; Patel M; Wang H; Boundy KE; Colon-Gonzalez F; Zang Y; Zhao X
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288637
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217
[TBL] [Abstract][Full Text] [Related]
19. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections.
Kuiper SG; Leegwater E; Wilms EB; van Nieuwkoop C
Expert Opin Pharmacother; 2020 Oct; 21(15):1805-1811. PubMed ID: 32820669
[TBL] [Abstract][Full Text] [Related]
20. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
Oliva ME; Rekha A; Yellin A; Pasternak J; Campos M; Rose GM; Babinchak T; Ellis-Grosse EJ; Loh E;
BMC Infect Dis; 2005 Oct; 5():88. PubMed ID: 16236177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]